Federal cannabis rescheduling signals a turning point, paving the way for institutional investors and reshaping regulations for DC, Maryland, and Virginia markets.

MJBizDaily reports cannabis multistate operators have given millions to President Donald Trump’s PACs, which may fund a staunchly anti-cannabis Senate hopeful. Here’s what it could mean.

Curaleaf lifted its hostile offer for Aurora Cannabis to $5 per share, saying its proposal relied on public data and calling for a fair process for shareholders.

A Texas case profiled by High Times shows how extreme cannabis penalties still happen. Here’s what DMV readers should consider about risk, compliance and delivery rules.

Florida advocates filed two separate adult-use cannabis initiatives that outline possession limits, sales via current dispensaries, and a licensing path—if they secure enough signatures.

Alabama’s health department dropped its opposition to federal marijuana rescheduling, per MJBizDaily. Here’s what changed, what’s unknown, and why DMV readers should care.

From West Virginia to Hawaii, lawmakers are prepping for FDA-approved psilocybin drugs—not legalizing mushrooms. Here’s what’s moving, who’s behind it, and how it could affect DMV residents.

New Cannabis Ventures covers Gemalgo's quantitative AI approach, separating cannabis tech analytics from traditional Wall Street quantitative finance.